ARKG vs IHI

Key Takeaways

• ARKG is an actively managed thematic ETF targeting the genomics revolution with a concentrated portfolio of 30-60 holdings, primarily in biotechnology and life sciences tools, while IHI is a passive ETF tracking a medical devices index with approximately 46-49 holdings focused exclusively on health care equipment manufacturers and distributors.
• ARK Genomic Revolution ETF (ARKG) carries a higher expense ratio of 0.75% compared to iShares U.S. Medical Devices ETF (IHI) at 0.37%, reflecting its active management style versus IHI's rules-based indexing approach.
• ARKG offers broader exposure across multiple sectors including health care, information technology, materials, energy, and consumer discretionary, whereas IHI provides targeted, nearly 100% allocation to the U.S. medical devices subsector within health care.
• Top holdings in ARKG emphasize innovative genomics companies such as 10x Genomics Inc. (TXG), Twist Bioscience Corp. (TWST), and Tempus AI Inc. (TEM), while IHI's largest positions include established medical device firms like Abbott Laboratories (ABT), Intuitive Surgical Inc. (ISRG), and Medtronic PLC (MDT).
• ARKG's active strategy allows for dynamic reallocation based on thematic conviction but introduces higher concentration risk, whereas IHI's passive structure delivers consistent market-cap weighted exposure with quarterly rebalancing and greater diversification within its niche.
• Both ETFs provide distinct avenues for health care sector exposure: ARKG through disruptive genomics innovation and IHI through stable medical equipment demand, making them complementary rather than direct competitors for investors seeking differentiated risk-return profiles.

Introduction

ARK Genomic Revolution ETF (ARKG) and iShares U.S. Medical Devices ETF (IHI) represent two specialized approaches to health care investing. ARKG pursues long-term capital growth through active selection of companies advancing the genomics revolution, while IHI delivers passive exposure to U.S. medical equipment firms. These ETFs do not compete directly but offer alternative strategies for investors targeting innovation-driven growth versus established device manufacturers. In the current market environment of advancing biotechnology and steady demand for medical technologies, comparing their structural features helps clarify positioning within broader health care allocations.

ARK Genomic Revolution ETF (ARKG) Overview

ARK Genomic Revolution ETF (ARKG) is an actively managed exchange-traded fund launched in 2014 that seeks long-term growth of capital by investing primarily in equity securities of companies relevant to the genomics revolution. The fund typically holds 30-60 positions and concentrates in health care, with significant allocations to biotechnology and life sciences tools and services. Top holdings often include 10x Genomics Inc. (TXG), Twist Bioscience Corp. (TWST), Tempus AI Inc. (TEM), CRISPR Therapeutics AG (CRSP), and Absci Corp. (ABSI). Its expense ratio stands at 0.75%. As a non-diversified, actively managed vehicle, ARKG employs high-conviction thematic selection with flexible rebalancing driven by fundamental research rather than mechanical rules.

iShares U.S. Medical Devices ETF (IHI) Overview

iShares U.S. Medical Devices ETF (IHI) is a passively managed fund launched in 2006 that seeks to track the Dow Jones U.S. Select Medical Equipment Index. The ETF holds approximately 46-49 securities and maintains nearly full exposure to health care equipment companies, including manufacturers and distributors of devices such as imaging systems, prosthetics, and surgical tools. Leading holdings typically feature Abbott Laboratories (ABT), Intuitive Surgical Inc. (ISRG), Medtronic PLC (MDT), Stryker Corp. (SYK), and Edwards Lifesciences Corp. (EW). Its expense ratio is 0.37%. IHI uses representative sampling for index replication and rebalances quarterly to maintain alignment with the underlying market-cap weighted benchmark.

Industry and Thematic Backdrop

The health care sector encompasses both high-growth innovation themes and stable equipment demand. Genomics and precision medicine continue to attract capital amid regulatory advancements and technological progress in gene editing and multiomics. Simultaneously, medical device manufacturers benefit from aging populations, elective procedure recovery, and ongoing hospital capital spending. Macroeconomic factors such as interest rate expectations and health care policy developments influence both areas, while sector risks include reimbursement pressures, clinical trial outcomes, and supply chain dependencies. These dynamics support differentiated exposure strategies within the broader health care universe.

Performance and Positioning Comparison

In recent market cycles, ARKG has exhibited higher volatility consistent with its concentrated active bets on emerging genomics companies and sensitivity to innovation news flow. IHI has delivered more stable returns tied to the steady cash flows and defensive characteristics of established medical device firms. During periods of sector rotation favoring growth themes, ARKG's thematic focus may amplify upside potential, whereas IHI's broad device exposure tends to provide ballast amid earnings cycles and macroeconomic shifts. Relative positioning reflects trade-offs between disruptive potential and operational resilience within health care.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Investors seeking data-driven insights on ETFs like ARKG and IHI can leverage this platform for efficient opportunity identification.

Tickeron AI Verdict

Based on observable structural factors including lower expense ratio, broader diversification within a stable subsector, and consistent passive indexing methodology, Tickeron’s AI would currently assign a higher probability of favor to iShares U.S. Medical Devices ETF (IHI) for investors prioritizing cost efficiency and sector stability. ARKG may appeal in environments emphasizing thematic innovation momentum, but IHI's profile aligns more closely with durable risk-adjusted characteristics in the current setting.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations